Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection.

Murata K, Tsukuda S, Suizu F, Kimura A, Sugiyama M, Watashi K, Noguchi M, Mizokami M.

Hepatology. 2019 Sep 17. doi: 10.1002/hep.30956. [Epub ahead of print]

PMID:
31529730
2.

Development of an in vitro cholestatic drug-induced liver injury evaluation system using HepG2-hNTCP-C4 cells in sandwich configuration.

Sakai Y, Okumura H, Iwao T, Watashi K, Ito K, Matsunaga T.

Toxicol In Vitro. 2019 Aug 5;61:104619. doi: 10.1016/j.tiv.2019.104619. [Epub ahead of print]

PMID:
31394163
3.

Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly.

Toyama M, Sakakibara N, Takeda M, Okamoto M, Watashi K, Wakita T, Sugiyama M, Mizokami M, Ikeda M, Baba M.

Virus Res. 2019 Oct 2;271:197677. doi: 10.1016/j.virusres.2019.197677. Epub 2019 Jul 31.

PMID:
31376401
4.

Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems.

Nio Y, Sasai M, Akahori Y, Okamura H, Hasegawa H, Oshima M, Watashi K, Wakita T, Ryo A, Tanaka Y, Hijikata M.

Antiviral Res. 2019 Sep;169:104537. doi: 10.1016/j.antiviral.2019.104537. Epub 2019 Jun 14.

PMID:
31207277
5.

An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferon-stimulated genes.

Furutani Y, Toguchi M, Shiozaki-Sato Y, Qin XY, Ebisui E, Higuchi S, Sudoh M, Suzuki H, Takahashi N, Watashi K, Wakita T, Kakeya H, Kojima S.

PLoS One. 2019 Jun 12;14(6):e0216139. doi: 10.1371/journal.pone.0216139. eCollection 2019.

6.

Small Interfering RNA Screening for the Small GTPase Rab Proteins Identifies Rab5B as a Major Regulator of Hepatitis B Virus Production.

Inoue J, Ninomiya M, Umetsu T, Nakamura T, Kogure T, Kakazu E, Iwata T, Takai S, Sano A, Fukuda M, Watashi K, Isogawa M, Tanaka Y, Shimosegawa T, McNiven MA, Masamune A.

J Virol. 2019 Jul 17;93(15). pii: e00621-19. doi: 10.1128/JVI.00621-19. Print 2019 Aug 1.

PMID:
31118260
7.

Retrotransposon elements among initial sites of hepatitis B virus integration into human genome in the HepG2-NTCP cell infection model.

Chauhan R, Shimizu Y, Watashi K, Wakita T, Fukasawa M, Michalak TI.

Cancer Genet. 2019 Jun;235-236:39-56. doi: 10.1016/j.cancergen.2019.04.060. Epub 2019 Apr 24.

PMID:
31064734
8.

Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization.

Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, Suzuki R, Aizaki H, Ryo A, Yun JH, Park SY, Ohtani N, Muramatsu M, Iwami S, Tanaka Y, Sureau C, Wakita T, Watashi K.

Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8487-8492. doi: 10.1073/pnas.1811064116. Epub 2019 Apr 5.

PMID:
30952782
9.

Concept of Viral Inhibitors via NTCP.

Fukano K, Tsukuda S, Watashi K, Wakita T.

Semin Liver Dis. 2019 Feb;39(1):78-85. doi: 10.1055/s-0038-1676804. Epub 2019 Jan 17. Review.

PMID:
30809790
10.

Screening for inhibitor of episomal DNA identified dicumarol as a hepatitis B virus inhibitor.

Takeuchi F, Ikeda S, Tsukamoto Y, Iwasawa Y, Qihao C, Otakaki Y, Ryota O, Yao WL, Narita R, Makoto H, Watashi K, Wakita T, Takeuchi K, Chayama K, Kogure A, Kato H, Fujita T.

PLoS One. 2019 Feb 19;14(2):e0212233. doi: 10.1371/journal.pone.0212233. eCollection 2019.

11.

Activation of protein kinase R by hepatitis C virus RNA-dependent RNA polymerase.

Suzuki R, Matsuda M, Shimoike T, Watashi K, Aizaki H, Kato T, Suzuki T, Muramatsu M, Wakita T.

Virology. 2019 Mar;529:226-233. doi: 10.1016/j.virol.2019.01.024. Epub 2019 Jan 29.

PMID:
30738360
12.

Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes.

Fukano K, Tsukuda S, Oshima M, Suzuki R, Aizaki H, Ohki M, Park SY, Muramatsu M, Wakita T, Sureau C, Ogasawara Y, Watashi K.

Front Microbiol. 2019 Jan 8;9:3257. doi: 10.3389/fmicb.2018.03257. eCollection 2018.

13.

Mathematical Analysis of a Transformed ODE from a PDE Multiscale Model of Hepatitis C Virus Infection.

Kitagawa K, Kuniya T, Nakaoka S, Asai Y, Watashi K, Iwami S.

Bull Math Biol. 2019 May;81(5):1427-1441. doi: 10.1007/s11538-018-00564-y. Epub 2019 Jan 14.

PMID:
30644067
14.

[From the Establishment of Hepatitis B Virus Cell Culture Systems to Drug Discovery].

Fukano K, Watashi K.

Yakugaku Zasshi. 2019;139(1):81-87. doi: 10.1248/yakushi.18-00164-4. Review. Japanese.

15.

Peroxiredoxin 1, a Novel HBx-Interacting Protein, Interacts with Exosome Component 5 and Negatively Regulates Hepatitis B Virus (HBV) Propagation through Degradation of HBV RNA.

Deng L, Gan X, Ito M, Chen M, Aly HH, Matsui C, Abe T, Watashi K, Wakita T, Suzuki T, Okamoto T, Matsuura Y, Mizokami M, Shoji I, Hotta H.

J Virol. 2019 Mar 5;93(6). pii: e02203-18. doi: 10.1128/JVI.02203-18. Print 2019 Mar 15.

16.

A Single Adaptive Mutation in Sodium Taurocholate Cotransporting Polypeptide Induced by Hepadnaviruses Determines Virus Species Specificity.

Takeuchi JS, Fukano K, Iwamoto M, Tsukuda S, Suzuki R, Aizaki H, Muramatsu M, Wakita T, Sureau C, Watashi K.

J Virol. 2019 Feb 19;93(5). pii: e01432-18. doi: 10.1128/JVI.01432-18. Print 2019 Mar 1.

17.

Acidic polysaccharides isolated from marine algae inhibit the early step of viral infection.

Ueno M, Nogawa M, Siddiqui R, Watashi K, Wakita T, Kato N, Ikeda M, Okimura T, Isaka S, Oda T, Ariumi Y.

Int J Biol Macromol. 2019 Mar 1;124:282-290. doi: 10.1016/j.ijbiomac.2018.11.152. Epub 2018 Nov 16.

PMID:
30452989
18.

High-throughput neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue virus type 1 reporter replicon.

Matsuda M, Yamanaka A, Yato K, Yoshii K, Watashi K, Aizaki H, Konishi E, Takasaki T, Kato T, Muramatsu M, Wakita T, Suzuki R.

Sci Rep. 2018 Nov 9;8(1):16624. doi: 10.1038/s41598-018-34865-y.

19.

The aryl hydrocarbon receptor-cytochrome P450 1A1 pathway controls lipid accumulation and enhances the permissiveness for hepatitis C virus assembly.

Ohashi H, Nishioka K, Nakajima S, Kim S, Suzuki R, Aizaki H, Fukasawa M, Kamisuki S, Sugawara F, Ohtani N, Muramatsu M, Wakita T, Watashi K.

J Biol Chem. 2018 Dec 21;293(51):19559-19571. doi: 10.1074/jbc.RA118.005033. Epub 2018 Oct 31.

PMID:
30381393
20.

Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development.

Hu J, Lin YY, Chen PJ, Watashi K, Wakita T.

Gastroenterology. 2019 Jan;156(2):338-354. doi: 10.1053/j.gastro.2018.06.093. Epub 2018 Sep 19. Review.

21.

IL-1β/ATF3-mediated induction of Ski2 expression enhances hepatitis B virus x mRNA degradation.

Shiromoto F, Aly HH, Kudo H, Watashi K, Murayama A, Watanabe N, Zheng X, Kato T, Chayama K, Muramatsu M, Wakita T.

Biochem Biophys Res Commun. 2018 Sep 10;503(3):1854-1860. doi: 10.1016/j.bbrc.2018.07.126. Epub 2018 Jul 25.

PMID:
30055801
22.

Screening of microRNAs for a repressor of hepatitis B virus replication.

Naito Y, Hamada-Tsutsumi S, Yamamoto Y, Kogure A, Yoshioka Y, Watashi K, Ochiya T, Tanaka Y.

Oncotarget. 2018 Jul 6;9(52):29857-29868. doi: 10.18632/oncotarget.25557. eCollection 2018 Jul 6.

23.

Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus.

Kitamura K, Que L, Shimadu M, Koura M, Ishihara Y, Wakae K, Nakamura T, Watashi K, Wakita T, Muramatsu M.

PLoS Pathog. 2018 Jun 21;14(6):e1007124. doi: 10.1371/journal.ppat.1007124. eCollection 2018 Jun.

24.

Development of a cell-based assay to identify hepatitis B virus entry inhibitors targeting the sodium taurocholate cotransporting polypeptide.

Miyakawa K, Matsunaga S, Yamaoka Y, Dairaku M, Fukano K, Kimura H, Chimuro T, Nishitsuji H, Watashi K, Shimotohno K, Wakita T, Ryo A.

Oncotarget. 2018 May 4;9(34):23681-23694. doi: 10.18632/oncotarget.25348. eCollection 2018 May 4.

25.

Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction.

Tsukamoto Y, Ikeda S, Uwai K, Taguchi R, Chayama K, Sakaguchi T, Narita R, Yao WL, Takeuchi F, Otakaki Y, Watashi K, Wakita T, Kato H, Fujita T.

PLoS One. 2018 May 21;13(5):e0197664. doi: 10.1371/journal.pone.0197664. eCollection 2018.

26.

De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry.

Passioura T, Watashi K, Fukano K, Shimura S, Saso W, Morishita R, Ogasawara Y, Tanaka Y, Mizokami M, Sureau C, Suga H, Wakita T.

Cell Chem Biol. 2018 Jul 19;25(7):906-915.e5. doi: 10.1016/j.chembiol.2018.04.011. Epub 2018 May 17.

27.

A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction.

Saso W, Tsukuda S, Ohashi H, Fukano K, Morishita R, Matsunaga S, Ohki M, Ryo A, Park SY, Suzuki R, Aizaki H, Muramatsu M, Sureau C, Wakita T, Matano T, Watashi K.

Biochem Biophys Res Commun. 2018 Jun 22;501(2):374-379. doi: 10.1016/j.bbrc.2018.04.187. Epub 2018 May 11.

PMID:
29730285
28.

Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide.

Nio Y, Akahori Y, Okamura H, Watashi K, Wakita T, Hijikata M.

Biochem Biophys Res Commun. 2018 Jun 27;501(3):820-825. doi: 10.1016/j.bbrc.2018.04.199. Epub 2018 May 4.

PMID:
29723527
29.

A PDE multiscale model of hepatitis C virus infection can be transformed to a system of ODEs.

Kitagawa K, Nakaoka S, Asai Y, Watashi K, Iwami S.

J Theor Biol. 2018 Jul 7;448:80-85. doi: 10.1016/j.jtbi.2018.04.006. Epub 2018 Apr 7.

PMID:
29634960
30.

Novel stable HBV producing cell line systems for expression and screening antiviral inhibitor of hepatitis B virus in human hepatoma cell line.

Ogura N, Ogawa K, Watashi K, Ito T, Wakita T.

Biochem Biophys Res Commun. 2018 Mar 25;498(1):64-71. doi: 10.1016/j.bbrc.2018.02.175. Epub 2018 Feb 24.

PMID:
29481805
31.

Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide.

Kaneko M, Futamura Y, Tsukuda S, Kondoh Y, Sekine T, Hirano H, Fukano K, Ohashi H, Saso W, Morishita R, Matsunaga S, Kawai F, Ryo A, Park SY, Suzuki R, Aizaki H, Ohtani N, Sureau C, Wakita T, Osada H, Watashi K.

Sci Rep. 2018 Feb 9;8(1):2769. doi: 10.1038/s41598-018-20987-w.

32.

Involvement of PUF60 in Transcriptional and Post-transcriptional Regulation of Hepatitis B Virus Pregenomic RNA Expression.

Sun S, Nakashima K, Ito M, Li Y, Chida T, Takahashi H, Watashi K, Sawasaki T, Wakita T, Suzuki T.

Sci Rep. 2017 Oct 9;7(1):12874. doi: 10.1038/s41598-017-12497-y.

33.

Functional association of cellular microtubules with viral capsid assembly supports efficient hepatitis B virus replication.

Iwamoto M, Cai D, Sugiyama M, Suzuki R, Aizaki H, Ryo A, Ohtani N, Tanaka Y, Mizokami M, Wakita T, Guo H, Watashi K.

Sci Rep. 2017 Sep 6;7(1):10620. doi: 10.1038/s41598-017-11015-4.

34.

ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells.

Scott T, Moyo B, Nicholson S, Maepa MB, Watashi K, Ely A, Weinberg MS, Arbuthnot P.

Sci Rep. 2017 Aug 7;7(1):7401. doi: 10.1038/s41598-017-07642-6.

35.

Hepatitis B virus prevents excessive viral production via reduction of cell death-inducing DFF45-like effectors.

Yasumoto J, Kasai H, Yoshimura K, Otoguro T, Watashi K, Wakita T, Yamashita A, Tanaka T, Takeda S, Moriishi K.

J Gen Virol. 2017 Jul;98(7):1762-1773. doi: 10.1099/jgv.0.000813.

PMID:
28745269
36.

Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments.

Ohashi H, Koizumi Y, Fukano K, Wakita T, Perelson AS, Iwami S, Watashi K.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4527-E4529. doi: 10.1073/pnas.1705234114. Epub 2017 May 16. No abstract available.

37.

Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection.

Sakurai F, Mitani S, Yamamoto T, Takayama K, Tachibana M, Watashi K, Wakita T, Iijima S, Tanaka Y, Mizuguchi H.

Sci Rep. 2017 Apr 4;7:45698. doi: 10.1038/srep45698.

38.

Establishment of a human hepatocellular cell line capable of maintaining long-term replication of hepatitis B virus.

Yao WL, Ikeda S, Tsukamoto Y, Shindo K, Otakaki Y, Qin M, Iwasawa Y, Takeuchi F, Kaname Y, Chou YC, Chang C, Watashi K, Wakita T, Noda T, Kato H, Fujita T.

Int Immunol. 2017 Mar 1;29(3):109-120. doi: 10.1093/intimm/dxx012.

PMID:
28338936
39.

Stereo-controlled synthesis of functionalized tetrahydropyridines based on the cyanomethylation of 1,6-dihydropyridines and generation of anti-hepatitis C virus agents.

Watanabe R, Mizoguchi H, Oikawa H, Ohashi H, Watashi K, Oguri H.

Bioorg Med Chem. 2017 Jun 1;25(11):2851-2855. doi: 10.1016/j.bmc.2017.03.011. Epub 2017 Mar 7.

PMID:
28314509
40.

Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE2-Mediated Suppression of Antitumor Immunity.

Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, Nakajima-Takagi Y, Iwama A, Koga T, Sugimoto Y, Ozawa T, Nakamura M, Kumagai M, Watashi K, Taketo MM, Aoki T, Narumiya S, Oshima M, Arita M, Hara E, Ohtani N.

Cancer Discov. 2017 May;7(5):522-538. doi: 10.1158/2159-8290.CD-16-0932. Epub 2017 Feb 15.

41.

Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.

Koizumi Y, Ohashi H, Nakajima S, Tanaka Y, Wakita T, Perelson AS, Iwami S, Watashi K.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1922-1927. doi: 10.1073/pnas.1610197114. Epub 2017 Feb 7. Erratum in: Proc Natl Acad Sci U S A. 2017 Mar 21;114(12 ):E2540-E2541.

42.

[Revealing the characteristics of antiviral agents].

Ohashi H, Watashi K.

Uirusu. 2017;67(2):133-142. doi: 10.2222/jsv.67.133. Japanese.

43.

Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.

Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T.

J Hepatol. 2017 Apr;66(4):685-692. doi: 10.1016/j.jhep.2016.11.009. Epub 2016 Nov 25.

PMID:
27890789
44.

Host factor PRPF31 is involved in cccDNA production in HBV-replicating cells.

Kinoshita W, Ogura N, Watashi K, Wakita T.

Biochem Biophys Res Commun. 2017 Jan 22;482(4):638-644. doi: 10.1016/j.bbrc.2016.11.085. Epub 2016 Nov 15.

PMID:
27864147
45.

A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.

Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, Omagari K, Suzuki R, Aizaki H, Kojima S, Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T.

Hepatology. 2017 Apr;65(4):1104-1116. doi: 10.1002/hep.28952. Epub 2017 Jan 17.

PMID:
27863453
46.

Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo.

Leong CR, Funami K, Oshiumi H, Mengao D, Takaki H, Matsumoto M, Aly HH, Watashi K, Chayama K, Seya T.

Oncotarget. 2016 Oct 18;7(42):68179-68193. doi: 10.18632/oncotarget.11907.

47.

Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative.

Ito W, Toyama M, Okamoto M, Ikeda M, Watashi K, Wakita T, Hashimoto Y, Baba M.

Antivir Chem Chemother. 2015 Dec;24(5-6):148-154. doi: 10.1177/2040206616663956. Epub 2016 Aug 19.

48.

Fungus-Derived Neoechinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System.

Nakajima S, Watashi K, Ohashi H, Kamisuki S, Izaguirre-Carbonell J, Kwon AT, Suzuki H, Kataoka M, Tsukuda S, Okada M, Moi ML, Takeuchi T, Arita M, Suzuki R, Aizaki H, Kato T, Suzuki T, Hasegawa H, Takasaki T, Sugawara F, Wakita T.

J Virol. 2016 Sep 29;90(20):9058-74. doi: 10.1128/JVI.00856-16. Print 2016 Oct 15.

49.

Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.

Tsunematsu S, Suda G, Yamasaki K, Kimura M, Izumi T, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Tanaka Y, Watashi K, Wakita T, Sakamoto N.

J Med Virol. 2017 Feb;89(2):267-275. doi: 10.1002/jmv.24643. Epub 2016 Aug 3.

PMID:
27459003
50.

Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus.

Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Miyoshi M, Tsunoda T, Nitta S, Asano Y, Nagata H, Otani S, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Nakauchi H, Nishitsuji H, Ujino S, Shimotohno K, Iwamoto M, Watashi K, Wakita T, Watanabe M.

Sci Rep. 2016 Jul 8;6:29358. doi: 10.1038/srep29358.

Supplemental Content

Loading ...
Support Center